Kynurenine pathway metabolism in human blood-brain-barrier cells: Implications for immune tolerance & neurotoxicity

Journal of Neurochemistry

Volumn 105, Issue 4, 2008, Pages 1346-1357

  Owe Young, Robert ^a,h   Webster, Nicole L ^b   Mukhtar, Muhammad ^c,i   Pomerantz, Roger J ^c,j   Smythe, George ^a   Walker, David ^d   Armati, Patricia J ^e   Crowe, Suzanne M ^b,f   Brew, Bruce J ^a,g,k  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d MONASH UNIVERSITY   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f MONASH UNIVERSITY   (Australia)

^g ST VINCENT S HOSPITAL   (Australia)

^h GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

ⁱ PMAS ARID AGRICULTURE UNIVERSITY   (Pakistan)

^j Tibotec Inc   (United States)

^k UNIVERSITY OF NEW SOUTH WALES   (Australia)

more..

Author keywords

Blood brain barrier; IDO; Immune tolerance; Neurotoxicity; Quinolinic acid; Tryptophan metabolism

Indexed keywords

GAMMA INTERFERON; KYNURENINE; PICOLINIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD BRAIN BARRIER; CELL VIABILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGICAL TOLERANCE; MACROPHAGE; MASS SPECTROMETRY; NEUROTOXICITY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BLOOD-BRAIN BARRIER; CELLS, CULTURED; ENDOTHELIAL CELLS; HUMANS; IMMUNE TOLERANCE; KYNURENINE; NEUROTOXICITY SYNDROMES; PERICYTES; SIGNAL TRANSDUCTION;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 42549112547     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2008.05241.x     Document Type: Article

References (53)

1. Abe S., Hu W., Ishibashi H., Hasumi K. Yamaguchi H. (2004) Augmented inhibition of Candida albicans growth by murine neutrophils in the presence of a tryptophan metabolite, picolinic acid. J Infect Chemother 10, 181 184.
2. Adam R., Russing D., Adams O., Ailyati A., Sik Kim K., Schroten H. Daubener W. (2005) Role of human brain microvascular endothelial cells during central nervous system infection. Significance of indoleamine 2,3-dioxygenase in antimicrobial defence and immunoregulation. Thromb. Haemost. 94, 341 346.
3. Adams O., Besken K., Oberdorfer C., MacKenzie C. R., Russing D. Daubener W. (2004) Inhibition of human herpes simplex virus type 2 by interferon gamma and tumor necrosis factor alpha is mediated by indoleamine 2,3-dioxygenase. Microbes Infect 6, 806 812.
4. Aggett P. J., Fenwick P. K. Kirk H. (1989) An in vitro study of the effect of picolinic acid on metal translocation across lipid bilayers. J. Nutr. 119, 1432 1437.
5. Beninger R. J., Colton A. M., Ingles J. L., Jhamandas K. Boegman R. J. (1994) Picolinic acid blocks the neurotoxic but not the neuroexcitant properties of quinolinic acid in the rat brain: evidence from turning behaviour and tyrosine hydroxylase immunohistochemistry. Neuroscience 61, 603 612.
6. Benveniste O., Vaslin B., Villinger F., Le Grand R., Ansari A. A. Dormont D. (1996) Cytokine mRNA levels in unmanipulated (ex vivo) and in vitro stimulated monkey PBMCs using a semi-quantitative RT-PCR and high sensitivity fluorescence-based detection strategy. Cytokine 8, 32 41.
7. Bosco M. C., Rapisarda A., Massazza S., Melillo G., Young H. Varesio L. (2000) The tryptophan catabolite picolinic acid selectively induces the chemokines macrophage inflammatory protein-1 alpha and -1 beta in macrophages. J. Immunol. 164, 3283 3291.
8. Cai S., Sato K., Shimizu T., Yamabe S., Hiraki M., Sano C. Tomioka H. (2006) Antimicrobial activity of picolinic acid against extracellular and intracellular Mycobacterium avium complex and its combined activity with clarithromycin, rifampicin and fluoroquinolones. J. Antimicrob. Chemother. 57, 85 93.
9. Daubener W., Spors B., Hucke C., Adam R., Stins M., Kim K. S. Schroten H. (2001) Restriction of Toxoplasma gondii growth in human brain microvascular endothelial cells by activation of indoleamine 2,3-dioxygenase. Infect. Immun. 69, 6527 6531.
10. Dykens J. A., Sullivan S. G. Stern A. (1987) Oxidative reactivity of the tryptophan metabolites 3-hydroxyanthranilate, cinnabarinate, quinolinate and picolinate. Biochem. Pharmacol. 36, 211 217.
11. Fallarino F., Grohmann U., You S., et al. (2006) The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 176, 6752 6761.
12. Feng H. M. Walker D. H. (2000) Mechanisms of intracellular killing of Rickettsia conorii in infected human endothelial cells, hepatocytes, and macrophages. Infect. Immun. 68, 6729 6736.
13. Fernandez-Pol J.A., Klos D. J. Hamilton P. D. (2001) Antiviral, cytotoxic and apoptotic activities of picolinic acid on human immunodeficiency virus-1 and human herpes simplex virus-2 infected cells. Anticancer Res. 21, 3773 3776.
14. Friberg M., Jennings R., Alsarraj M., Dessureault S., Cantor A., Extermann M., Mellor A. L., Munn D. H. Antonia S. J. (2002) Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int. J. Cancer 101, 151 155.
15. Frumento G., Rotondo R., Tonetti M., Damonte G., Benatti U. Ferrara G. B. (2002) Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 196, 459 468.
16. Goldstein L. E., Leopold M. C., Huang X., et al. (2000) 3-Hydroxykynurenine and 3-hydroxyanthranilic acid generate hydrogen peroxide and promote alpha-crystallin cross-linking by metal ion reduction. Biochemistry 39, 7266 7275.
17. Grohmann U., Fallarino F. Puccetti P. (2003) Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol 24, 242 248.
18. Guillemin G. J., Kerr S. J., Smythe G. A., Smith D. G., Kapoor V., Armati P. J., Croitoru J. Brew B. J. (2001) Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J. Neurochem. 78, 842 853.
19. Heyes M. P., Brew B. J., Martin A., Price R. W., Salazar A. M., Sidtis J. J., Yergey J. A., Mouradian M. M., Sadler A. E. Keilp J. (1991) Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann. Neurol. 29, 202 209.
20. Heyes M. P., Saito K. Markey S. P. (1992) Human macrophages convert L-tryptophan into the neurotoxin quinolinic acid. Biochem. J. 283, 633 635.
21. Heyes M. P., Jordan E. K., Lee K., Saito K., Frank J. A., Snoy P. J., Markey S. P. Gravell M. (1992) Relationship of neurologic status in macaques infected with the simian immunodeficiency virus to cerebrospinal fluid quinolinic acid and kynurenic acid. Brain Res. 570, 237 250.
22. Hu B., Hissong B. D. Carlin J. M. (1995) Interleukin-1 enhances indoleamine 2,3-dioxygenase activity by increasing specific mRNA expression in human mononuclear phagocytes. J. Interferon Cytokine Res. 15, 617 624.
23. Hunt N. H., Golenser J., Chan-Ling T., Parekh S., Rae C., Potter S., Medana I. M., Miu J. Ball H. J. (2006) Immunopathogenesis of cerebral malaria. Int. J. Parasitol. 36, 569 582.
24. Ishii T., Iwahashi H., Sugata R., Kido R. Fridovich I. (1990) Superoxide dismutases enhance the rate of autoxidation of 3-hydroxyanthranilic acid. Arch. Biochem. Biophys. 276, 248 250.
25. Jhamandas K. H., Boegman R. J., Beninger R. J. Flesher S. (1998) Role of zinc in blockade of excitotoxic action of quinolinic acid by picolinic acid. Amino Acids 14, 257 261.
26. Kalisch B. E., Jhamandas K., Boegman R. J. Beninger R. J. (1994) Picolinic acid protects against quinolinic acid-induced depletion of NADPH diaphorase containing neurons in the rat striatum. Brain Res. 668, 1 8.
27. Kerr S. J., Armati P. J. Brew B. J. (1995) Neurocytotoxity of quinolinic acid in human brain cultures. J. Neurovirol. 1, 375 380.
28. Kerr S. J., Armati P. J., Guillemin G. J. Brew B. J. (1998) Chronic exposure of human neurons to quinolinic acid results in neuronal changes consistent with AIDS dementia complex. AIDS 12, 355 363.
29. Kerr S. J., Armati P. J., Pemberton L. A., Smythe G., Tattam B. Brew B. J. (1997) Kynurenine pathway inhibition reduces neurotoxicity of HIV-1-infected macrophages. Neurology 49, 1671 1681.
30. Mellor A. L., Chandler P., Baban B., Hansen A. M., Marshall B., Pihkala J., Waldmann H., Cobbold S., Adams E. Munn D. H. (2004) Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int. Immunol. 16, 1391 1401.
31. Moffett J. R. Namboodiri M. A. (2003) Tryptophan and the immune response. Immunol. Cell Biol. 81, 247 265.
32. Mukhtar M., Harley S., Chen P., BouHamdan M., Patel C., Acheampong E. Pomerantz R. J. (2002) Primary isolated human brain microvascular endothelial cells express diverse HIV/SIV-associated chemokine coreceptors and DC-SIGN and L-SIGN. Virology 297, 78 88.
33. Munn D. H. Mellor A. L. (2004) IDO and tolerance to tumors. Trends Mol Med 10, 15 18.
34. Munn D. H., Sharma M. D. Mellor A. L. (2004) Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J. Immunol. 172, 4100 4110.
35. Nemeth H., Toldi J. Vecsei L. (2005) Role of kynurenines in the central and peripheral nervous systems. Curr Neurovasc Res 2, 249 260.
36. Nicholls T., Nitsos I., Smythe G. Walker D. W. (2001) Kynurenine production and catabolism in fetal sheep with embolized or nonembolized placentas. Am. J. Obstet. Gynecol. 185, 988 995.
37. Pais T. F. Appelberg R. (2000) Macrophage control of mycobacterial growth induced by picolinic acid is dependent on host cell apoptosis. J. Immunol. 164, 389 397.
38. Poljak A., Grant R., Austin C.J., Jamie J. F., Willows R. D., Takikawa O., Littlejohn T. K., Truscott R. J., Walker M. J., Sachdev P. Smythe G. A. (2006) Inhibition of indoleamine 2,3 dioxygenase activity by H2O2. Arch. Biochem. Biophys. 450, 9 19.
39. Saito K., Markey S. P. Heyes M. P. (1992) Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse. Neuroscience 51, 25 39.
40. Schlingemann R. O., Rietveld F. J., de Waal R. M., Ferrone S. Ruiter D. J. (1990) Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. Am. J. Pathol. 136, 1393 405.
41. Schroten H., Spors B., Hucke C., Stins M., Kim K. S., Adam R. Daubener W. (2001) Potential role of human brain microvascular endothelial cells in the pathogenesis of brain abscess: inhibition of Staphylococcus aureus by activation of indoleamine 2,3-dioxygenase. Neuropediatrics 32, 206 210.
42. Shimizu T. Tomioka H. (2006) Activity of picolinic acid in combination with the antiprotozoal drug quinacrine against Mycobacterium avium complex. Antimicrob. Agents Chemother. 50, 3186 3188.
43. Smith D. G., Guillemin G. J., Pemberton L., Kerr S., Nath A., Smythe G. A. Brew B. J. (2001) Quinolinic acid is produced by macrophages stimulated by platelet activating factor, Nef and Tat. J. Neurovirol. 7, 56 60.
44. Smythe G. A., Braga O., Brew B. J., Grant R. S., Guillemin G. J., Kerr S. J. Walker D. W. (2002) Concurrent quantification of quinolinic, picolinic, and nicotinic acids using electron-capture negative-ion gas chromatography-mass spectrometry. Anal. Biochem. 301, 21 26.
45. Stazka J., Luchowski P., Wielosz M., Kleinrok Z. Urbanska E. M. (2002) Endothelium-dependent production and liberation of kynurenic acid by rat aortic rings exposed to L-kynurenine. Eur. J. Pharmacol. 448, 133 137.
46. Stone T. W. (1993) Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 45, 309 379.
47. Stone T. W. (2000) Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection. Trends Pharmacol Sci 21, 149 154.
48. Stone T. W. Addae J. I. (2002) The pharmacological manipulation of glutamate receptors and neuroprotection. Eur. J. Pharmacol. 447, 285 296.
49. Stone T. W. Darlington L. G. (2002) Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov 1, 609 620.
50. Takikawa O., Kuroiwa T., Yamazaki F. Kido R. (1988) Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. J. Biol. Chem. 263, 2041 2048.
51. Takikawa O., Tagawa Y., Iwakura Y., Yoshida R. Truscott R. J. (1999) Interferon-gamma-dependent/independent expression of indoleamine 2,3-dioxygenase. Studies with interferon-gamma-knockout mice. Adv. Exp. Med. Biol. 467, 553 557.
52. Wacker H. H., Hansmann M. L., Lumbeck H., Radzun H. J. Parwaresch M. R. (1990) A new pan-macrophage antibody Ki-M1P stains plasmacytoid cells in paraffin sections of lymph nodes. Verh Dtsch Ges Pathol 74, 159 164.
53. Wejksza K., Rzeski W., Parada-Turska J., Zdzisinska B., Rejdak R., Kocki T., Okuno E., Kandefer-Szerszen M., Zrenner E. Turski W. A. (2004) Kynurenic acid production in cultured bovine aortic endothelial cells. Homocysteine is a potent inhibitor. Naunyn Schmiedebergs Arch Pharmacol 369, 300 304.